AQUESTIVE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.07 USD | +3.56% |
|
-0.85% | +101.49% |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Aquestive Therape...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Companyâs Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.07
USD
Average target price
9
USD
Spread / Average Target
+121.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +101.49% | 368M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- AQST Stock
- News Aquestive Therapeutics, Inc.
- Transcript : Aquestive Therapeutics, Inc., Q4 2023 Earnings Call, Mar 06, 2024
